XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Reportable Segment Information (Tables)
 9 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment for the three and nine months ended June 30, 2022 and 2021.

 

Three months ended

 

 

Nine months ended

 

 

June 30

 

 

June 30

 

(In millions - unaudited)

2022

 

 

2021

 

 

2022

 

 

2021

 

SALES

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

228

 

 

$

193

 

 

$

602

 

 

$

548

 

Personal Care

 

172

 

 

 

147

 

 

 

490

 

 

 

409

 

Specialty Additives

 

194

 

 

 

169

 

 

 

532

 

 

 

474

 

Intermediates

 

73

 

 

 

49

 

 

 

192

 

 

 

118

 

Intersegment sales (a)

 

(23

)

 

 

(15

)

 

 

(57

)

 

 

(29

)

 

$

644

 

 

$

543

 

 

$

1,759

 

 

$

1,520

 

OPERATING INCOME (LOSS)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

51

 

 

$

37

 

 

$

115

 

 

$

101

 

Personal Care

 

25

 

 

 

16

 

 

 

67

 

 

 

49

 

Specialty Additives (b)

 

35

 

 

 

15

 

 

 

79

 

 

 

36

 

Intermediates

 

30

 

 

 

11

 

 

 

72

 

 

 

17

 

Unallocated and other

 

(64

)

 

 

(34

)

 

 

(121

)

 

 

(92

)

 

$

77

 

 

$

45

 

 

$

212

 

 

$

111

 

DEPRECIATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

9

 

 

$

9

 

 

$

25

 

 

$

26

 

Personal Care

 

10

 

 

 

10

 

 

 

28

 

 

 

29

 

Specialty Additives

 

16

 

 

 

16

 

 

 

48

 

 

 

49

 

Intermediates

 

2

 

 

 

4

 

 

 

9

 

 

 

10

 

Unallocated and other

 

—

 

 

 

1

 

 

 

1

 

 

 

1

 

 

$

37

 

 

$

40

 

 

$

111

 

 

$

115

 

AMORTIZATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

7

 

 

$

7

 

 

$

21

 

 

$

21

 

Personal Care

 

11

 

 

 

11

 

 

 

35

 

 

 

30

 

Specialty Additives

 

5

 

 

 

5

 

 

 

14

 

 

 

14

 

Intermediates

 

1

 

 

 

—

 

 

 

1

 

 

 

—

 

 

$

24

 

 

$

23

 

 

$

71

 

 

$

65

 

EBITDA (c)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

67

 

 

$

53

 

 

$

161

 

 

$

148

 

Personal Care

 

46

 

 

 

37

 

 

 

130

 

 

 

108

 

Specialty Additives

 

56

 

 

 

36

 

 

 

141

 

 

 

99

 

Intermediates

 

33

 

 

 

15

 

 

 

82

 

 

 

27

 

Unallocated and other

 

(64

)

 

 

(33

)

 

 

(120

)

 

 

(91

)

 

$

138

 

 

$

108

 

 

$

394

 

 

$

291

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30

 

 

September 30

 

(In millions - unaudited)

2022

 

 

2021

 

TOTAL ASSETS

 

 

 

 

 

Life Sciences

$

1,938

 

 

$

1,945

 

Personal Care

 

1,087

 

 

 

1,145

 

Specialty Additives

 

1,601

 

 

 

1,636

 

Intermediates

 

185

 

 

 

160

 

Unallocated and other

 

1,601

 

 

 

1,726

 

 

$

6,412

 

 

$

6,612

 

 

 

 

 

 

 
(a)
Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment transfers are accounted for at cost.
(b)
Includes a capital project impairment of $9 million for the nine months ended June 30, 2021 relating to a long-term capital project plan change at a plant facility.
(c)
Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and income (loss) on acquisitions and divestitures, net. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.